# IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial

**Authors:** Sheng-Li Xue, Mei-Jing Liu, Chong-Sheng Qian, Su-Ning Chen, Hui-Ying Qiu, Li-Qing Kang, Hai-Ping Dai, Wen-Jie Gong, Li-Yun Chen, Zhen Yao, Ming-Zhu Xu, Hai-Xia Zhou, Xiao-Fei Yang, Qian Wu, Xue-Qing Dou, Jian Zhang, Yin Liu, Qing-Ya Cui, Zheng Li, Yang Xu, Man Qiao, Tong-Tong Zhang, Jing-Wen Tan, Nan Xu, Ming-Hao Li, Zhou Yu, Xiao-Yan Lou, Wei Wang, Hong-Jia Zhu, Lu Qin, Lei Yu, Xiao-Wen Tang, De-Pei Wu

PMC · DOI: 10.1038/s41408-025-01397-4 · 2025-10-27

## Full-text entities

- **Genes:** CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** acute lymphoblastic leukemia (MESH:D054198)
- **Chemicals:** ssCART-19 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12559308/full.md

---
Source: https://tomesphere.com/paper/PMC12559308